Tempest Therapeutics is a biopharmaceutical company, focused on developing treatments for endocrine diseases. Co.'s three product candidates are: Livoletide (AZP-531), which is for the treatment Prader-Willi syndrome, a genetic endocrine disease usually characterized by hyperphagia, or insatiable hunger; nevanimibe (ATR-101), which is a potential treatment for patients with congenital adrenal hyperplasia, a monogenic adrenal disease that requires lifelong treatment with exogenous cortisol, often at high doses; and NK3R antagonist (MLE-301), which is a potential treatment of vasomotor symptoms commonly known as hot flashes and night sweats, in menopausal women. The TPST stock yearly return is shown above.
The yearly return on the TPST stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TPST annual return calculation with any dividends reinvested as applicable (on ex-dates).
|